Advertisement

Regional Liver-Directed Therapies for Intrahepatic Cholangiocarcinoma

  • Nikitha Murali
  • Lynn Jeanette Savic
  • Nariman Nezami
  • Julius Chapiro
  • Jean-François GeschwindEmail author
Chapter

Abstract

Patients with unresectable intrahepatic cholangiocarcinoma (ICC) have a poor prognosis and have historically benefited from very few treatment options. In the last 10 years, image-guided locoregional therapies have been developed to administer targeted treatment to the liver and are increasingly used in primary hepatic malignancies such as ICC. Locoregional therapies primarily consist of ablation and intra-arterial therapies, including conventional transarterial chemoembolization (cTACE), TACE with drug-eluting beads (DEB-TACE), and yttrium-90 radioembolization (Y90-RE). Current clinical evidence suggests that these treatments result in prolonged survival without significantly diminishing patient’s quality of life. This chapter aims to describe each locoregional therapy and the clinical evidence supporting its therapeutic application to unresectable ICC.

Keywords

Intrahepatic cholangiocarcinoma (ICC) Locoregional therapy Intra-arterial therapy Transarterial chemoembolization cTACE DEB-TACE Y90-RE Radiation Ablation 

References

  1. 1.
    Buettner S, van Vugt JL, JN IJ, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131–42.CrossRefGoogle Scholar
  2. 2.
    Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.CrossRefGoogle Scholar
  3. 3.
    Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806–13.CrossRefGoogle Scholar
  4. 4.
    Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(2):101–4.CrossRefGoogle Scholar
  5. 5.
    Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90(4):817–37.CrossRefGoogle Scholar
  6. 6.
    Kim Y, Moris DP, Zhang XF, Bagante F, Spolverato G, Schmidt C, et al. Evaluation of the 8th edition American joint commission on cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol. 2017;116(6):643–50.CrossRefGoogle Scholar
  7. 7.
    Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189–200.CrossRefGoogle Scholar
  8. 8.
    Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.CrossRefGoogle Scholar
  9. 9.
    Valls C, Guma A, Puig I, Sanchez A, Andia E, Serrano T, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25(5):490–6.CrossRefGoogle Scholar
  10. 10.
    Tillich M, Mischinger HJ, Preisegger KH, Rabl H, Szolar DH. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol. 1998;171(3):651–8.CrossRefGoogle Scholar
  11. 11.
    Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004;9(1):43–57.CrossRefGoogle Scholar
  12. 12.
    Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565–74.CrossRefGoogle Scholar
  13. 13.
    Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr. 2017;6(1):7–21.CrossRefGoogle Scholar
  14. 14.
    Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217(4):736–50 e4.CrossRefGoogle Scholar
  15. 15.
    Lee JI, Campbell JS. Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol. 2014;61(2):432–4.CrossRefGoogle Scholar
  16. 16.
    Wang K, Zhang H, Xia Y, Liu J, Shen F. Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(2):79–90.CrossRefGoogle Scholar
  17. 17.
    Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):22–34.CrossRefGoogle Scholar
  18. 18.
    Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma--a population-based study. Ann Surg Oncol. 2008;15(2):600–8.CrossRefGoogle Scholar
  19. 19.
    Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–79.CrossRefGoogle Scholar
  20. 20.
    Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193(4):384–91.CrossRefGoogle Scholar
  21. 21.
    Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.CrossRefGoogle Scholar
  22. 22.
    Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811–8.CrossRefGoogle Scholar
  23. 23.
    Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779–86.CrossRefGoogle Scholar
  24. 24.
    Yamada R, Nakatsuka H, Nakamura K, Sato M, Itami M, Kobayashi N, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26(2):81–96.PubMedGoogle Scholar
  25. 25.
    Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J. 2008;14(2):117–22.CrossRefGoogle Scholar
  26. 26.
    Minami Y, Kudo M. Imaging modalities for assessment of treatment response to nonsurgical hepatocellular carcinoma therapy: contrast-enhanced US, CT, and MRI. Liver Cancer. 2015;4(2):106–14.CrossRefGoogle Scholar
  27. 27.
    Cohen MJ, Levy I, Barak O, Bloom AI, Fernandez-Ruiz M, Di Maio M, et al. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int. 2014;34(7):1109–17.CrossRefGoogle Scholar
  28. 28.
    Vogl TJ, Naguib NN, Nour-Eldin NE, Bechstein WO, Zeuzem S, Trojan J, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer. 2012;131(3):733–40.CrossRefGoogle Scholar
  29. 29.
    Pomoni M, Malagari K, Moschouris H, Spyridopoulos TN, Dourakis S, Kornezos J, et al. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepato-Gastroenterology. 2012;59(115):820–5.PubMedGoogle Scholar
  30. 30.
    Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16(3):353–61.CrossRefGoogle Scholar
  31. 31.
    Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35(9):2083–91.CrossRefGoogle Scholar
  32. 32.
    Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011;117(7):1498–505.CrossRefGoogle Scholar
  33. 33.
    Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg. 2008;12(1):129–37.CrossRefGoogle Scholar
  34. 34.
    Scheuermann U, Kaths JM, Heise M, Pitton MB, Weinmann A, Hoppe-Lotichius M, et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience. Eur J Surg Oncol. 2013;39(6):593–600.CrossRefGoogle Scholar
  35. 35.
    Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12(8):2563–7.CrossRefGoogle Scholar
  36. 36.
    Lewis AL, Dreher MR, O'Byrne V, Grey D, Caine M, Dunn A, et al. DC BeadM1: towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med. 2016;27(1):13.CrossRefGoogle Scholar
  37. 37.
    Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31(5):883–8.CrossRefGoogle Scholar
  38. 38.
    Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol. 2014;37(1):154–64.CrossRefGoogle Scholar
  39. 39.
    Poggi G, Amatu A, Montagna B, Quaretti P, Minoia C, Sottani C, et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2009;32(6):1187–92.CrossRefGoogle Scholar
  40. 40.
    Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18(2):431–8.CrossRefGoogle Scholar
  41. 41.
    Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43.PubMedGoogle Scholar
  42. 42.
    Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251–78.CrossRefGoogle Scholar
  43. 43.
    Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–91.CrossRefGoogle Scholar
  44. 44.
    Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440–8.CrossRefGoogle Scholar
  45. 45.
    Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105–16.CrossRefGoogle Scholar
  46. 46.
    Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.CrossRefGoogle Scholar
  47. 47.
    Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc. 2009;70(3):561–7.CrossRefGoogle Scholar
  48. 48.
    Rodriguez-Lago I, Carretero C, Herraiz M, Subtil JC, Betes M, Rodriguez-Fraile M, et al. Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. World J Gastroenterol. 2013;19(19):2935–40.CrossRefGoogle Scholar
  49. 49.
    Mosconi C, Cappelli A, Ascanio S, Pettinari I, Modestino F, Renzulli M, et al. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncol. 2017;13(15):1301–10.CrossRefGoogle Scholar
  50. 50.
    Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198.CrossRefGoogle Scholar
  51. 51.
    Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113(8):2119–28.CrossRefGoogle Scholar
  52. 52.
    Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.CrossRefGoogle Scholar
  53. 53.
    Hickey R, Mulcahy MF, Lewandowski RJ, Gates VL, Vouche M, Habib A, et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88(5):1025–31.CrossRefGoogle Scholar
  54. 54.
    Xu HX, Wang Y, Lu MD, Liu LN. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol. 2012;85(1016):1078–84.CrossRefGoogle Scholar
  55. 55.
    Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):2–6.CrossRefGoogle Scholar
  56. 56.
    Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg. 2002;68(4):395–7.PubMedGoogle Scholar
  57. 57.
    Simo KA, Halpin LE, McBrier NM, Hessey JA, Baker E, Ross S, et al. Multimodality treatment of intrahepatic cholangiocarcinoma: a review. J Surg Oncol. 2016;113(1):62–83.CrossRefGoogle Scholar
  58. 58.
    Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol. 2015;26(7):943–8.CrossRefGoogle Scholar
  59. 59.
    Giorgio A, Calisti G, DE Stefano G, Farella N, DI Sarno A, Amendola F, et al. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single Centre experience. Anticancer Res. 2011;31(12):4575–80.PubMedGoogle Scholar
  60. 60.
    Carrafiello G, Lagana D, Cotta E, Mangini M, Fontana F, Bandiera F, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol. 2010;33(4):835–9.CrossRefGoogle Scholar
  61. 61.
    Zhang SJ, Hu P, Wang N, Shen Q, Sun AX, Kuang M, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2013;20(11):3596–602.CrossRefGoogle Scholar
  62. 62.
    Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol. 2011;80(3):e221–5.CrossRefGoogle Scholar
  63. 63.
    Yu MA, Liang P, Yu XL, Cheng ZG, Han ZY, Liu FY, et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur J Radiol. 2011;80(2):548–52.CrossRefGoogle Scholar
  64. 64.
    Schnapauff D, Denecke T, Grieser C, Collettini F, Seehofer D, Sinn M, et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2012;35(3):581–7.CrossRefGoogle Scholar
  65. 65.
    Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15(11):1279–86.CrossRefGoogle Scholar
  66. 66.
    Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol. 2011;21(4):287–93.CrossRefGoogle Scholar
  67. 67.
    Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr. 2017;6(2):105–16.CrossRefGoogle Scholar
  68. 68.
    Weiner AA, Olsen J, Ma D, Dyk P, DeWees T, Myerson RJ, et al. Stereotactic body radiotherapy for primary hepatic malignancies - report of a phase I/II institutional study. Radiother Oncol. 2016;121(1):79–85.CrossRefGoogle Scholar
  69. 69.
    Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer. 2015;6(11):1099–104.CrossRefGoogle Scholar
  70. 70.
    Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol. 2016;34(3):219–26.CrossRefGoogle Scholar
  71. 71.
    Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–8.CrossRefGoogle Scholar
  72. 72.
    Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10(6):507–20.CrossRefGoogle Scholar
  73. 73.
    Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2.CrossRefGoogle Scholar
  74. 74.
    Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100(11):2426–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Nikitha Murali
    • 1
  • Lynn Jeanette Savic
    • 1
    • 2
  • Nariman Nezami
    • 1
    • 3
  • Julius Chapiro
    • 1
    • 3
  • Jean-François Geschwind
    • 4
    Email author
  1. 1.Department of Diagnostic RadiologyYale University School of MedicineNew HavenUSA
  2. 2.Department of Radiology and Biomedical ImagingYale School of MedicineNew HavenUSA
  3. 3.Department of Radiology and Biomedical ImagingYale New Haven Hospital, Yale School of MedicineNew HavenUSA
  4. 4.PreScience Labs LLCWestportUSA

Personalised recommendations